Keywords
germ cell tumor, cecal mass, chemotherapy
germ cell tumor, cecal mass, chemotherapy
Extra gonadal germ cell tumors (EGCTs) are rare and account for 1–3% of all the gonadal tumors1–3. Several mechanism have been described, including possible migration of pluripotent stem cells, which convert to germ cells during embryonic development. The usual sites of EGCTs are mediastinum, retro-peritoneal organs, and pineal gland1–4. Involvement of gastrointestinal tract is rare and is very unlikely in the absence of a primary elsewhere. Shogbesan et al. reported an EGCT presenting as duodenal mass with primary tumor identified in the testis. There are a few cases reported in literature without an identifiable primary in the gonads; none of which presented as a cecal mass1,2.
A 23 year old Caucasian male who worked part-time as a waiter at a restaurant, with no significant past medical history presented during the fall of 2018 to the emergency department with increasing abdominal pain, diarrhea, and episodic vomiting for 3 weeks. Review of systems was positive for melena and shortness of breath on exertion. Family history was only relevant for an aunt who died from lung cancer. He had a five pack year smoking history and smokes marijuana socially. On admission, he was tachycardic and febrile, and exam revealed cachexia with bitemporal wasting. Fullness and irregularity in the right ileac fossa with associated tenderness was noted on palpation of the abdomen. See Figure 1 for full timeline.
Computed tomography (CT) of the abdomen revealed a cecal mass with multiple metastases to liver, lungs and abdominal lymph nodes (Figure 2, Figure 3). Colonoscopy was performed, but the endoscope was unable to be advanced beyond the cecal mass. The tumor was poorly differentiated, and urothelial carcinoma was in the differential due to the positive GATA3 immunohistochemical staining. Liver biopsy reported an undifferentiated metastatic carcinoma. Beta HCG (human chorionic gonadotropin) level was 118,789 IU/L. After the elevated beta HCG level was detected, the colonic specimen was stained with the markers for germ cell tumors (beta HCG and PLAP) which was positive. Ultrasound of the scrotum was done to look for a primary tumor, which was negative. Magnetic resonance imaging (MRI) of the brain and a CT scan of the chest did not reveal any growth in the pineal gland or mediastinum, respectively.
Chemotherapy was started with Bleomycin (30 units/wk IV on days 1, 8 and 15 regimen), Etoposide (100 mg/m2/day IV ) and Cisplatin ( 20 mg/m2/day IV on days 1–5); given the high Beta HCG levels and deteriorating clinical status. Within 7 days of starting this regimen, beta HCG levels dropped dramatically to 31,163 IU/L. During the course of hospitalization the patient developed symptomatic small bowel obstruction with perforation, which was confirmed with a CT scan. Colonic resection was performed. The resected mass was identified to be germ cell tumor as it picked up beta HCG, SALL4, GATA3, OCT 4 as well as PLAP stains on histo-path exam (Figure 4, Figure 5).
The patient responded to chemotherapy initially with a drop in HCG levels; however, hospital course was complicated with tumor lysis syndrome and neutropenic sepsis, which progressed to multi-organ dysfunction. He required mechanical ventilatory support along with vasopressors for blood pressure support. As a result of deterioration, the family opted for comfort care measures. The patient expired 36 hours later. Even though his cancer burden was responding to chemotherapy, he unfortunately succumbed from complications of the treatment.
EGCTs are considered metastatic from an occult or “burned out” gonadal cancer if a primary testicular tumor is not apparent. An ultrasound of the scrotum should always be performed to rule out a testicular tumor. A gonadal biopsy to rule out such tumor is not recommended5. The patient in the present study was found to have an EGCT in the cecum and colon. Similar to GCTs, EGCTs are sensitive to radiotherapy and chemotherapy.
Currently, common drugs used for chemotherapy include cisplatin, etoposide and bleomycin6–9. Our patient received these medications along with surgery which helped in reducing his tumor burden. The International Germ Cell Cancer Collaboration Group (IGCCCG) places the patients into poor prognosis category if they are found to have a primary tumor or visceral metastases elsewhere apart from the lungs and retro peritoneum. The 5-year survival rate in such patients is 48%4,10–12.
This case demonstrates one of the rare presentations of extra-gonadal germ cell tumors and the diagnostic challenges associated with it. Early diagnosis entails high index of suspicion, especially in young males presenting with tumor of unknown origin. Early recognition of this presentation will help in reducing the tumor burden and the mortality associated with it. It also allow for early treatment, which usually entails surgery (for accessible tumors) along with chemotherapy. However, our knowledge about these tumors and their presentations is still limited, and as seen in this patient, treatment can result in complications well. This limitation warrants the need for studies on EGCTs and their management.
Gonadal tumors should be among the differentials in patients presenting with abdominal mass, especially in younger adults.
The importance of this case is to identify a constellation of symptoms, obscurities, diagnostic difficulties, adverse effects of treatment of an extra gonadal germ cell tumor.
The authors would encourage testing with Beta HCG in young males presenting with a tumor of unknown origin.
The authors would also encourage a multidisciplinary approach with surgery and early initiation of chemotherapy in such patients to control the disease burden.
This report also increases awareness that one should be watchful for complications after implementing treatment with chemotherapy, as early detection of complication may help prevent negative outcomes.
Written informed consent for publication of their clinical details and clinical images was obtained from the parent of the patient.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
References
1. Abell M, Fayos J, Lampe I: Retroperitoneal germinomas (seminomas) without evidence of testicular involvement. Cancer. 1965; 18 (3): 273-290 Publisher Full TextCompeting Interests: No competing interests were disclosed.
Is the background of the case’s history and progression described in sufficient detail?
Yes
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly
Is the case presented with sufficient detail to be useful for other practitioners?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Testicular germ cell tumor
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 10 Oct 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)